Sivia Capital Partners LLC Acquires New Position in Medpace Holdings, Inc. $MEDP

Key Points

• Sivia Capital Partners LLC acquired 944 shares of Medpace Holdings, Inc. worth approximately $296,000 in the second quarter, as reported in their recent 13F filing.
• Medpace's stock has shown a 14.2% increase in revenue year-over-year, reporting $603.31 million in quarterly revenue against analysts' expectations of $537.70 million.
• Insider selling has occurred, with the General Counsel and CFO collectively selling 15,000 shares totaling over $6.8 million, indicating a significant reduction in their ownership positions.

Sivia Capital Partners LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 944 shares of the company's stock, valued at approximately $296,000.

A number of other hedge funds have also made changes to their positions in MEDP. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Brooklyn Investment Group raised its holdings in Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after purchasing an additional 71 shares in the last quarter. Whittier Trust Co. lifted its position in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after buying an additional 35 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Medpace in the 1st quarter valued at $60,000. Finally, Assetmark Inc. boosted its holdings in shares of Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after buying an additional 43 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Insider Transactions at Medpace

In other news, CEO August J. Troendle sold 36,196 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $475.90, for a total value of $17,225,676.40. Following the completion of the sale, the chief executive officer directly owned 925,799 shares of the company's stock, valued at $440,587,744.10. This trade represents a 3.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of Medpace stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the sale, the chief financial officer owned 6,000 shares in the company, valued at approximately $2,725,380. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 161,266 shares of company stock valued at $74,111,427 over the last 90 days. Insiders own 20.30% of the company's stock.

Medpace Stock Down 0.1%

MEDP stock traded down $0.52 during trading on Monday, hitting $498.08. The company had a trading volume of 155,854 shares, compared to its average volume of 316,492. The firm has a 50-day moving average price of $450.44 and a 200-day moving average price of $356.61. The firm has a market cap of $13.99 billion, a PE ratio of 37.03, a price-to-earnings-growth ratio of 3.14 and a beta of 1.44. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $506.55.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. During the same period last year, the firm earned $2.75 EPS. The firm's revenue for the quarter was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on MEDP shares. UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and boosted their price target for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. Jefferies Financial Group lifted their target price on Medpace from $400.00 to $450.00 and gave the stock a "hold" rating in a research report on Tuesday, September 9th. TD Cowen reissued a "sell" rating and issued a $366.00 target price (up from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Rothschild Redb downgraded Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 3rd. Finally, Mizuho lifted their price target on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus price target of $422.27.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.